GenKardia: Funding, Investors & Team (Oct 2026)
GenKardia's goal is to provide new treatments that enhance the quality of life for individuals facing Heart Failure.
GenKardia has raised $250k across 1 funding round on record, the most recent an undisclosed round of $250k announced in May 2025.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
GenKardia Company Profile and Key Stats
Latest funding round on record: May 2025.
GenKardia Funding Rounds
GenKardia Founders and Leadership Team
No contact details are on record for this team yet.
GenKardia Funding Compared to Other Biotechnology Startups
GenKardia's latest round of $250k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like GenKardia in Biotechnology and New York
Companies Similar to GenKardia
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
GenKardia Funding FAQs
What does GenKardia do?
GenKardia's goal is to provide new treatments that enhance the quality of life for individuals facing Heart Failure.
How much funding has GenKardia raised?
GenKardia has raised $250k across 1 round on record. The most recent is an undisclosed round of $250k announced in May 2025.
When did GenKardia last raise funding?
GenKardia's most recent funding round on record is an undisclosed round of $250k, announced in May 2025.
Who founded GenKardia?
FundedIQ lists Richard Nkulikiyinka (Founder) at GenKardia.
Where is GenKardia headquartered?
GenKardia is based in New York, United States.
How many employees does GenKardia have?
GenKardia is in the 1-10 employee band.
How does GenKardia's funding compare to other Biotechnology startups?
GenKardia's latest round of $250k is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's GenKardia Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for GenKardia is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.